New stroke pill aims to boost brain recovery and prevent second strokes

NCT ID NCT06674460

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a sublingual tablet (edaravone dexborneol) can improve outcomes for people who recently had a stroke due to small vessel disease. About 600 adults aged 30–80 will receive either the tablet or a placebo for 24 weeks, with follow-up for one year. The goal is to see if the treatment reduces disability, prevents another stroke, and helps preserve thinking and memory.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cerebral Small Vessel Diseases ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••